2 Trillion Won Big Deal Targeting Rare Bleeding Disorders

Incyte Corporation (INCY) announced on July 6 that it has completed its acquisition of Vega Therapeutics, finalizing the deal with an upfront payment of $1.25 billion and up to $750 million in sales milestones, for a total potential consideration of $2 billion. Through this transaction, the Phase III monoclonal antibody candidate VGA039, aimed at bleeding disorders such as von Willebrand disease, will join Incyte’s hematology portfolio. The company plans to recognize the upfront acquisition payment as a one-time research and development expense in its third-quarter and full-year 2026 results.

According to the company and media reports, VGA039 has received FDA Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations. The acquisition marks Incyte’s expansion into the bleeding-disorders segment of its hematology business. In its 2025 earnings report, the company highlighted revenue growth and provided a business outlook for 2026, noting continued growth in its existing blood-cancer and oncology portfolio.

Headquartered in Delaware, Incyte Corporation is a global biopharmaceutical company focused on developing treatments in hematology, oncology, inflammation and autoimmune diseases. The rare bleeding-disorders market, characterized by a small patient population, limited treatment options and high drug prices, is seen as an area of intense competition among major pharmaceutical and biotech companies seeking new drug candidates.